Bruno Linetzky is an Executive Director of R&D for Tirzepatide Obesity-Nilex at Eli Lilly and Company, specializing in SURMOUNT-MMO. With an MD and PhD in Medicine, they have served as a Senior Global Medical Advisor for Empagliflozin in heart failure and held the position of Clinical Research Physician within the Global Medical Affairs team. Their previous experiences include being a Medical Liaison at Sanofi Aventis and the National Manager of Argentina’s Non-communicable Disease Surveillance System. Bruno also possesses a Master's degree in Clinical Effectiveness and has actively participated in initiatives such as the PURE study focused on cardiovascular epidemiology.
This person is not in the org chart
This person is not in any teams
This person is not in any offices